Company

Bank

Analyst

Coverage

Opinion

Wk chg

2/7 cls

Fluidigm Corp. (NASDAQ:FLDM)

Cowen

Doug Schenkel

Downgrade

Market perform (from outperform)

-4%

$43.11

Schenkel raised his target to $45 from $42, saying the company's single-cell genomics technologies and 2014 outlook are captured in the stock's price. Fluidigm reported 2013 revenues of $71.2M and expects a 23-28% increase in 2014. Schenkel is "increasingly weary" of the company's increased concentration in sample preparation vs. the higher revenue-generating analytical tools base. Fluidigm is acquiring DVS Sciences Inc., which develops and markets single-cell protein analysis systems, for about $207.5M in a cash and stock deal (see BioCentury, Feb. 3).

Gilead Sciences Inc. (NASDAQ:GILD)

Baird

Brian Skorney

Upgrade

Outperform (from neutral)

-2%

$78.75

Skorney also raised his target to $103 from $65 after Gilead reported 4Q13 and 2013 EPS and revenues that beat the Street and provided the first official sales figures for HCV drug Sovaldi sofosbuvir (see "EPS Watch," A19). Gilead recorded $139.4M in 4Q13 sales of Sovaldi, which was launched in the U.S. in December and approved in Europe in January. Skorney said Sovaldi is "selling way beyond our expectations," and raised his sales estimate to $6.3B in 2014 and $15.4B in 2015.